Medication info
New Esopra Tablet 40 mg (Esomeprazole Magnesium Trihydrate)

New Esopra Tablet 40 mg (Esomeprazole Magnesium Trihydrate)

Prescription medicationTabletOral · Intravenous injection
Ingredient · strength
Esomeprazole Magnesium Trihydrate›44.5mg / 1 tablet
Manufacturer / importer
AhnGook NewPharm Co., Ltd.
Appearance
Pink round film-coated tablets
Packaging
28 tablets (14 tablets/PTP) x 2, 30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 201604269 · Approved 2016.07.11 · Insurance code 053600370

Summary

Main use
Treatment of reflux disease, gastrointestinal disorders (ulcers, Helicobacter pylori infection, etc.), and Zollinger-Ellison syndrome
Who uses it
Adults · Children
Adult dosage
This medicine should be swallowed with a liquid such as water; do not chew or crush it. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis is not healed or symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. · Once symptoms have resolved, control subsequent recurring symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug treatment. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drug use (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. Clinical trials lasting more than 4 weeks have not been conducted. 4) Patients requiring continuous nonsteroidal anti-inflammatory drug treatment - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with a dose of 80 ∼ 160 mg per day. Doses above 80 mg per day should be divided into 2 doses. 6) Maintenance therapy after intravenous induction of prevention of rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks after intravenous induction of prevention of rebleeding from gastric or duodenal ulcers. 4. Renal impairment No dose adjustment is necessary. Use with caution because experience administering this medicine to patients with severe renal failure is limited. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Older adults No dose adjustment is necessary.
Children's dosage
2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis is not healed or symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. · Once symptoms have resolved, control subsequent recurring symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug treatment. 3. Children under 12 years of age There is no experience with administering this medicine to children under 12 years of age.

Ingredients

Manufacturer
AhnGook NewPharm Co., Ltd.

Efficacy & effects

Treatment of reflux disease, gastrointestinal disorders (ulcers, Helicobacter pylori infection, etc.), and Zollinger-Ellison syndrome

  • Gastroesophageal reflux disease
  • erosive esophagitis
  • esophagitis
  • duodenal ulcer
  • peptic ulcer
  • upper gastrointestinal pain
  • upper gastrointestinal discomfort
  • upper gastrointestinal burning sensation
  • gastric ulcer
  • duodenal ulcer
  • Zollinger-Ellison syndrome
View approved original text

This medication can be used for a long time to treat gastroesophageal reflux disease and erosive esophagitis and to prevent the recurrence of esophagitis. It is also effective in the treatment of duodenal ulcers and peptic ulcers caused by Helicobacter pylori, and helps prevent recurrence. It is effective in treating upper gastrointestinal symptoms or gastric ulcers and prevention associated with the use of NSAIDs. It is used to treat Zollinger-Ellison syndrome and is also applied as maintenance therapy to prevent rebleeding from gastric or duodenal ulcers after intravenous administration. Overall, this drug is used to improve and treat various gastrointestinal diseases.

Dosage and Administration

Adult dosage

This medicine should be swallowed with a liquid such as water; do not chew or crush it. 1. Adults 1) Gastroesophageal reflux disease (GERD). - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis is not healed or symptoms persist, continue treatment for an additional 4 weeks. - Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once daily - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. · Once symptoms have resolved, control subsequent recurring symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug treatment. 2) Combination therapy with antibiotics for Helicobacter pylori eradication Administer this medicine 20 mg with amoxicillin 1 g and clarithromycin 500 mg twice daily for 7 days. 3) Short-term treatment of upper gastrointestinal symptoms (pain, discomfort, burning sensation) associated with nonsteroidal anti-inflammatory drug use (nonselective or selective COX-2 inhibitors) - 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. Clinical trials lasting more than 4 weeks have not been conducted. 4) Patients requiring continuous nonsteroidal anti-inflammatory drug treatment - Treatment of gastric ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. The treatment period is 4∼8 weeks. - Prevention of gastric and duodenal ulcers associated with nonsteroidal anti-inflammatory drug use: 20 mg once daily. 5) Treatment of Zollinger-Ellison syndrome The recommended initial dose is 40 mg twice daily. The dose should then be adjusted for each patient, and treatment should continue while clinical symptoms are present. Clinical data indicate that most patients can be controlled with a dose of 80 ∼ 160 mg per day. Doses above 80 mg per day should be divided into 2 doses. 6) Maintenance therapy after intravenous induction of prevention of rebleeding from gastric or duodenal ulcers Administer 40 mg once daily for 4 weeks after intravenous induction of prevention of rebleeding from gastric or duodenal ulcers. 4. Renal impairment No dose adjustment is necessary. Use with caution because experience administering this medicine to patients with severe renal failure is limited. 5. Hepatic impairment No dose adjustment is necessary in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment, the dose of this medicine should not exceed 20 mg. 6. Older adults No dose adjustment is necessary.

Children's dosage

2. Adolescents aged 12 years and older 1) Gastroesophageal reflux disease (GERD) - Treatment of erosive reflux esophagitis: Administer 40 mg once daily for 4 weeks. If esophagitis is not healed or symptoms persist, continue treatment for an additional 4 weeks. - Symptomatic treatment of gastroesophageal reflux disease without esophagitis: · 20 mg once daily. If symptoms are not controlled after 4 weeks, further medical evaluation is required. · Once symptoms have resolved, control subsequent recurring symptoms by administering 20 mg once daily. · In adults, 20 mg may be administered once daily as needed. As-needed administration to control recurring symptoms is not recommended for patients at high risk of developing gastric and duodenal ulcers due to nonsteroidal anti-inflammatory drug treatment. 3. Children under 12 years of age There is no experience with administering this medicine to children under 12 years of age.

Precautions

This drug should not be used in patients with known allergies to this drug or its components. Particularly, caution is needed when co-administering this drug with penicillin-type antibiotics or macrolide antibiotics in patients with allergies to these medications. Additionally, it is advisable that patients taking certain heart-related medications or antiviral drugs, and nursing mothers or patients with a history of myocardial infarction do not use this drug. This drug may cause various side effects, with headache, abdominal pain, diarrhea, dizziness, and skin rash being commonly reported. Rarely, hematological abnormalities, liver dysfunction, severe allergic reactions, or muscular problems may occur, so if any unusual symptoms appear, immediate consultation with a healthcare professional is necessary. If taking this drug for an extended period, regular checks to confirm any abnormalities are important. As this drug suppresses gastric acid secretion, it may increase the risk of certain bacterial infections. There may be an increased risk of fractures; therefore, bone health should be regularly monitored in long-term use. Further, this drug is highly likely to interact with other medications, so if taking other drugs, it is essential to inform the healthcare professional. During pregnancy, safety data on this drug are limited, thus it should be used cautiously, and it is recommended to avoid administering this drug while breastfeeding. In case of overdose, since no specific antidote is available, treatment should be provided based on the symptoms, and it must be stored in a place out of reach of children.

Side effects

Leukopenia, thrombocytopenia, agranulocytosis, pancytopenia, fever, angioedema, anaphylactic reaction, shock, peripheral edema, hyponatremia, hypomagnesemia, insomnia, anxiety, mental confusion, depression, aggression, hallucination, headache, dizziness, paresthesia, drowsiness, taste disturbance, blurred vision, bronchospasm, pancreatitis, abdominal pain, constipation, diarrhea, abdominal distention, nausea, vomiting, dry mouth, stomatitis, gastrointestinal candidiasis, microscopic colitis, increased liver enzymes, hepatitis, liver failure, encephalopathy, dermatitis, pruritus, rash, urticaria, hair loss, photosensitivity, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, drug reactions with eosinophilia and systemic symptoms, fracture, arthralgia, myalgia, muscle weakness, interstitial nephritis, gynecomastia, asthenia, increased sweating, Clostridium difficile-associated diarrhea, abdominal distension, allergic reaction, back pain, chest pain, sternal pain, facial swelling, facial flushing, fatigue, fever, influenza-like illness, generalized edema, leg edema, malaise, pain, rigidity, peripheral edema, flushing, hypertension, tachycardia, thyroid gland enlargement, irritable bowel syndrome, exacerbation of constipation, dyspepsia, dysphagia, gastrointestinal motility disorders, upper abdominal pain, belching, esophageal disorders, frequent bowel movements, gastroenteritis, gastrointestinal hemorrhage, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased serum gastrin, tongue disorders, tongue swelling, ulcerative stomatitis, vomiting, earache, tinnitus, anemia, hypopigmented anemia, cervical lymphadenopathy, epistaxis, leukocytosis, leukopenia, thrombocytopenia, hyperbilirubinemia, liver function abnormalities, increased ALT, increased AST, diabetes, hyperuricemia, increased ALP, thirst, vitamin B12 deficiency, weight gain, weight loss, exacerbation of arthritis, arthropathy, convulsions, fibromyalgia syndrome, hernia, rheumatologic polymyalgia, arthralgia, loss of appetite, apathy, increased appetite, confusion, exacerbation of depression, hypertonia, anxiety, sensory loss, erectile dysfunction, insomnia, migraine, exacerbation of migraine, sleep disorders, tremor, dizziness, visual field defect, paresthesia, drowsiness, dysmenorrhea, menstrual disorders, vaginitis, exacerbation of asthma, cough, dyspnea, laryngeal edema, pharyngitis, rhinitis, sinusitis, acne, anal pruritus, rash, erythematous rash, papular rash, angioedema, dermatitis, pruritus, urticaria, increased sweating, otitis media, altered sense of smell, taste loss, taste disorder, urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, urinary frequency, candidiasis, genital candidiasis, polyuria, conjunctivitis, visual disturbances, duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyp or nodule, Barrett's esophagus, mucosal discoloration, hernia, systemic lupus erythematosus, cutaneous lupus erythematosus, gastric epithelial polyp, hypocalcemia, hypokalemia, rhabdomyolysis, myalgia, asthenia

Not everyone experiences these, and they can vary from person to person.

Storage

This drug should be contained in a sealed container and stored at temperatures between 1°C and 30°C in a cool, dry place, avoiding direct sunlight.

Appearance and packaging

Appearance

Pink round film-coated tablets

Package unit

28 tablets (14 tablets/PTP) x 2, 30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.